INVA
What one share of Innoviva holds
Pharmaceutical Preparations
Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets.
Innoviva’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.19 |
|---|---|
| Profit | $4.31 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $2.23 |
| Cash and investments | $7.85 |
| Debt | $3.56 |
| Book value | $16.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.08 | $0.53 | $0.00 | $0.49 | $0.00 | −$3.23 |
| 2017 | $1.81 | $1.17 | $0.00 | $1.18 | $0.00 | −$2.39 |
| 2018 | $2.30 | $3.53 | $0.00 | $1.97 | — | $1.52 |
| 2019 | $2.30 | $1.43 | $0.00 | $2.27 | — | $3.10 |
| 2020 | $2.97 | $2.02 | $0.00 | $2.76 | — | $5.33 |
| 2021 | $4.16 | $2.87 | $0.00 | $3.86 | — | $5.96 |
| 2022 | $3.48 | $2.37 | $0.00 | $2.12 | — | $8.18 |
| 2023 | $3.57 | $2.20 | $0.00 | $1.62 | — | $10.66 |
| 2024 | $4.84 | $0.36 | $0.00 | $2.54 | — | $11.03 |
| 2025 | $4.85 | $3.30 | $0.01 | $2.31 | — | $15.71 |